Several inhibitors targeting MDM2-p53 such as RG7112, RG7388, RG7775, SAR405838, HDM201, APG-115, AMG-232, and MK-8242 have recently been developed to treat human cancers with clinical trials. Here, MDM2 is linked to cancer.